<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33760283</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2990</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Neuropathology and applied neurobiology</Title><ISOAbbreviation>Neuropathol Appl Neurobiol</ISOAbbreviation></Journal><ArticleTitle>An autopsy case of pure nigropathy with TUBA4A nonsense mutation.</ArticleTitle><Pagination><StartPage>891</StartPage><EndPage>893</EndPage><MedlinePgn>891-893</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/nan.12712</ELocationID><Abstract><AbstractText>We showed the results of pathological and genetic investigation for an autopsy case who was evaluated as longstanding Parkinson's disease (PD) in alive. Neuropathological investigation showed "pure nigropathy" without Lewy and tau pathology, and genetic analyses using next-generation sequencing detected novel TUBA4A nonsence mutation. Subsequent physiological study added to strength the hypothesis that the variant is pathogenic one. Present case showed TUBA4A is not only responsible gene for amyotrophic lateral sclerosis/frontotemporal dementia but also PD associated pure nigropathy. Also we found minimal but significant tau pathology high possibly associated with long-term deep brain stimulation in subthalamic nucleus.</AbstractText><CopyrightInformation>&#xa9; 2021 British Neuropathological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Okada</LastName><ForeName>Keitaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University of Toyama School of Medicine, Toyama, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Legal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hata</LastName><ForeName>Yukiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Legal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ichimata</LastName><ForeName>Shojiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Legal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Legal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oku</LastName><ForeName>Yuko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Legal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asahi</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Kanazawa Neurosurgical Hospital, Ishikawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishida</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-6921-1768</Identifier><AffiliationInfo><Affiliation>Department of Legal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropathol Appl Neurobiol</MedlineTA><NlmUniqueID>7609829</NlmUniqueID><ISSNLinking>0305-1846</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018389">Codon, Nonsense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C408046">TUBA8 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014404">Tubulin</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C566288">Frontotemporal Dementia With Motor Neuron Disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018389" MajorTopicYN="N">Codon, Nonsense</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014404" MajorTopicYN="N">Tubulin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>24</Day><Hour>13</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33760283</ArticleId><ArticleId IdType="doi">10.1111/nan.12712</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Kunath T, Natalwala A, Chan C, et al. Are PARKIN patients ideal candidates for dopaminergic cell replacement therapies? Eur J Neurosci. 2019;49:453-462.</Citation></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389-404.</Citation></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503-1527.</Citation></Reference><Reference><Citation>Schneider SA, Alcalay RN. Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature. Mov Disord. 2017;32:1504-1523.</Citation></Reference><Reference><Citation>Smith B, Ticozzi N, Fallini C, et al. Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. Neuron. 2014;84:324-331.</Citation></Reference><Reference><Citation>Pensato V, Tiloca C, Corrado L, et al. TUBA4A gene analysis in sporadic amyotrophic lateral sclerosis: identification of novel mutations. J Neurol. 2015;262:1376-1378.</Citation></Reference><Reference><Citation>Perrone F, Nguyen HP, Van Mossevelde S, et al. Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients. Neurobiol Aging. 2017;51(177):e9-e16.</Citation></Reference><Reference><Citation>Li J, He J, Tang L, et al. Screening for TUBA4A mutations in a large Chinese cohort of patients with ALS: re-evaluating the pathogenesis of TUBA4A in ALS. J Neurol Neurosurg Psychiatry. 2018;89:1350-1352.</Citation></Reference><Reference><Citation>Uchino A, Takao M, Hatsuta H, et al. Incidence and extent of TDP-43 accumulation in aging human brain. Acta Neuropathol Commun. 2015;3:35.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>